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Drug resistance still impedes successful cancer chemotherapy. A major goal of early 
concepts in individualized therapy was to develop in vitro tests to predict tumors’ drug 
responsiveness. We have developed an in vitro short-term test based on nucleic acid 
precursor incorporation to determine clinical drug resistance. This test detects inherent 
and acquired resistance in vitro and transplantable syngeneic and xenografted tumors 
in vivo. In several clinical trials, clinical resistance was predictable with more than 90% 
accuracy, while drug sensitivity was detected with less accuracy (~60%). Remarkably, 
clinical cross-resistance to numerous drugs (multidrug resistance, broad spectrum
resistance) was detectable by a single compound, doxorubicin, due to its multifactorial 
modes of action. The results of this predictive test were in good agreement with pre-
dictive assays of other authors. As no predictive test has been established as yet for 
clinical diagnostics, the identification of sensitive drugs may not reach sufficiently high 
reliability for clinical routine. A meta-analysis of the literature published during the past 
four decades considering test results of more than 15,000 tumor patients unambiguously 
demonstrated that, in the majority of studies, resistance was correctly predicted with an 
accuracy between 80 and 100%, while drug sensitivity could only be predicted with an 
accuracy of 50–80%. This synopsis of the published literature impressively illustrates that 
prediction of drug resistance could be validated. The determination of drug resistance 
was reliable independent of tumor type, test assay, and drug used in these in vitro tests. 
By contrast, chemosensitivity could not be predicted with high reliability. Therefore, we 
propose a rethinking of the “chemosensitivity” concept. Instead, predictive in vitro tests 
may reliably identify drug-resistant tumors. The clinical consequence imply to subject 
resistant tumors not to chemotherapy, but to other new treatment options, such as 
antibody therapy, adoptive immune therapy, hyperthermia, gene therapy, etc. The high 
accuracy to predict resistant tumors may be exploited to develop new strategies for indi-
vidualized cancer therapy. This new concept bears the potential of a revival of predictive 
tests for personalized medicine.
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iNTRODUCTiON
Chemotherapy of malignant tumors is essentially based on 
the results of prospective, randomized, double-blind phase III 
studies and corresponding clinical guidelines. However, the 
clinical response of the individual patient still remains uncertain, 
although the statistical probability of treatment success is known 
within large groups of patients from clinical studies. Tumors dif-
fer in their molecular architecture and biological behavior from 
patient to patient and even within the same tumor. There is a 
large heterogeneity between different subpopulations of tumor 
cells.
Drug resistance is a major reason for failure of cancer chemo-
therapy. In present clinical practice, drug resistance can only be 
recognized during larger periods of treatment. It, therefore, would 
be of great value for each individual patient to determine resistance 
before commencing treatment with antineoplastic substances. In 
nearly 50% of all cancer cases, resistance to chemotherapy already 
exists before drug treatment (1). Meanwhile, the knowledge of 
various resistance mechanisms has increased over the years (2, 
3). While the responsiveness of tumor cells to targeted anti-
cancer drugs (e.g., HER2- or estrogen-receptor-targeting small 
molecules) can be predicted by pre-therapeutic determination of 
their corresponding targets, the situation is more complicated for 
clinically long established cytotoxic drugs, where the molecular 
targets are either less well-defined or which have broader modes of 
action. Here, diagnostic tests are desirable to predict the response 
of tumors to treatment. If a tumor is resistant, therapy might only 
give rise to toxic effects in various normal tissues without having 
any major influence on tumor growth (4). The question therefore 
arises, whether the general clinical recommendations are optimal 
or whether they need to be improved by resistance testing.
Many different methods to assay sensitivity or resistance of 
tumors to chemotherapy have been developed over the last dec-
ades (5, 6). We used a test in which a cell suspension is prepared 
from fresh tumor biopsies. The cells are incubated over 3 h with 
cytostatic test drugs and the uptake of radioactive nucleic acid 
precursors (3H-thymidine or 3H-uridine) is determined during 
the last hour of incubation (7, 8). The important advantages of our 
test procedure are (1) its simplicity, (2) that the cells do not need 
to be long-term cultured before testing, and (3) that practically 
all tumor types can be tested. This review gives a synopsis of this 
test system.
Detection of Acquired Resistance
The usefulness of any resistance test depends on the degree, to 
which in vitro results are correlated with clinical results. To prove 
an in vitro short-term test to detect drug resistance, we generated 
different tumor lines, which were resistant toward doxorubicin, 
daunorubicin, cytosine-arabinoside, or cyclophosphamide (9, 
10). As exemplarily shown in Figure 1A, sensitive and doxoru-
bicin-resistant sarcoma 180 ascites tumor cells grown in mice 
were used. After treatment with doxorubicin over 25 passages, 
resistance to this drug was developed in animals (Figure  1A, 
left). This doxorubicin resistance was also detectable using this 
in vitro short-term test (Figure 1A, middle). Upon doxorubicin 
treatment, mice bearing resistant (pre-treated) tumor cells 
revealed significantly shorter survival times than mice with non-
pre-treated tumor cells.
In addition to determination of resistance at a given time point, 
it was also possible to detect gradual increase or decrease during 
the development or reversion of resistance in tumor lines (12).
Detection of inherent Resistance
Walker carcinosarcoma and neurosarcoma both grown subcuta-
neously as solid tumors in rats provide suitable models as rapidly 
and slowly growing tumors, respectively. If left untreated, rats 
bearing Walker carcinosarcoma survived for 10 days and those 
bearing neurosarcoma for 10  weeks. The tumors responded 
to drug treatment in a growth rate-dependent manner. For 
example, doxorubicin had only weak effects on neurosarcoma, 
whereas the growth of Walker carcinosarcoma was appreciably 
inhibited by the same concentrations of doxorubicin (Figure 1B, 
left). This different proliferation-dependent sensitivity was also 
observed in the in vitro short-term test (Figure 1B, middle). We 
have obtained similar results with other transplantation tumors 
(adenocarcinoma, sarcoma S180, melanoma FIII, and multiple 
myeloma) grown in different species (mouse, rat, and hamster) 
(Figure 1B, right) (7).
The results obtained in few transplantation tumors were con-
firmed in large panels of animal and human carcinomas. Some 
carcinomas were very strongly affected by doxorubicin, whereas 
others showed no or only moderate effects. This variable tumor 
response to doxorubicin was correlated with the proliferation rate 
of these tumors (Figure 1C, left). A comparison between animal 
transplantation tumors and clinical human tumor specimens 
showed that animal tumors tend to be more sensitive than human 
ones (Figure 1C, middle). In general, tumors with high incorpo-
ration rates of nucleic acid precursors showed more pronounced 
inhibitory effects and vice versa (13).
To explore the relevance of proliferation-dependent drug 
response for patient survival, we investigated fresh surgical speci-
mens of previously untreated ovarian carcinomas (Figure  1C, 
right) (11). All patients underwent surgery and subsequent 
chemotherapy, and all patients had a minimum of 5  years of 
follow up. Patients with highly proliferative tumors (proportion 
of SG2M-phase cells >17% as measured by flow cytometry) had 
shorter survival times than those with low proliferating tumors 
(proportion of SG2M-phase cells ≤17%) (p = 0.01). Similar results 
were obtained with lung carcinomas (14). This is in agreement 
with the general clinical observation that cancer chemotherapy 
is most successful, if applied for rapidly growing malignant cells 
(Figure 1C, right) (13).
CLiNiCAL STUDieS
Survival curves differed, if patients were distributed into two 
groups on the basis of the in vitro short-term test with doxorubicin. 
Patients with in vitro resistant tumors died sooner than in vitro 
sensitive ones. Lung cancer patients, who refused chemotherapy 
lived on average only as long as patients with in vitro resistant 
tumors (8).
Results of these clinical pilot studies encouraged us to start a 
controlled clinical trial predominantly in ovarian and lung cancer, 
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but also in other tumor types (Figure 2). In a multi-centric trial 
conducted by nine different hospitals, results obtained by the 
in vitro short-term test were compared with the clinical response 
of patients (15). Seventy-two patients with ovarian carcinoma, 
24 patients with lung carcinoma, and 18 patients with various 
other tumor types were treated according to standardized therapy 
schedules (5-fluorouracil and cyclophosphamide for ovary 
carcinoma, cyclophosphamide, methotrexate, 5-fluorouracil 
for lung cancer) (Figure  2A). The remaining patients received 
different therapy regimens. Using the in  vitro short-term test, 
dose–response curves were generated for doxorubicin as well as 
5-fluorouracil and 4-OOH-cyclophosphamide (the in vitro active 
metabolite of cyclophosphamide). Remarkably, doxorubicin was 
most accurate compound compared to the other two drugs to 
predict clinical responsiveness to chemotherapy (Figure  2A) 
independent of the specific therapy regimen.
Summing up the results of all tumors studied in this trial, we 
have 151 matched comparisons of in vitro test results and clinical 
response rates to chemotherapy (Figure  2A). Of them, 76 had 
been classified as resistant and 75 as sensitive by the in vitro short-
term test. Of the 76 tumors resistant in vitro, 56 were clinically 
progressive (73%), two were in remission and 19 (25%) showed 
no change. The 75 in vitro sensitive tumors showed the following 
clinical courses: 18 (24%) were progressive, 40 (53%) were in 
remission, and 17 (23%) were unchanged. If only strict clinical 
criteria (progression or remission) were applied and compared to 
the in vitro test results, 55 of the 57 in vitro resistant tumors were 
clinically progressive (96%) and only 40 of 58 in vitro sensitive 
tumors reached clinical remission (69%) (Figure 2A). Thus, drug 
resistance was predictable with high accuracy, but not drug sen-
sitivity. Furthermore, drug resistance has been detected in vitro 
by doxorubicin with high accuracy, even if this substance had 
not been included in the clinical therapy regimens. By contrast, 
it was not possible to predict in  vitro drug-specific sensitivity 
in primary, non-pre-treated human carcinomas with the same 
degree of accuracy.
To see whether or not our own results reflect the situation 
observed by other investigators, we performed a survey of all drug 
sensitivity/resistance results published since 1980 until today. As 
a first step, we extracted the test results of more than 3600 cancer 
patients and compared the prediction of sensitivity or resistance 
in vitro with the clinical treatment response (Table 1, upper part). 
The vast majority of publications reported that the prediction of 
drug resistance was possible with much higher accuracy than pre-
diction of drug sensitivity. In the majority of studies, resistance 
was correctly predicted with an accuracy between 80 and 100%, 
while drug sensitivity could only be predicted with an accuracy 
of only 50–80%. As a next step, we compared our own evaluation 
of published data with meta-analyses performed by other authors 
(Table 1, lower part). The numbers of patients of all published 
papers exceeded 15,000. Remarkably again, drug resistance 
could be predicted with high reliability, but not sensitivity. This 
synopsis of the published literature of four decades impressively 
illustrates that the concept of prediction of chemosensitivity was 
not validated. By contrast, the determination of drug resistance 
was reliable independent of tumor type, test assay, and drug used 
in these in vitro tests.
Figures 2B,C show that the in vitro test results were in good 
agreement with patients’ survival. Patients, whose tumors were 
resistant in the in vitro short-term test, died earlier than patients, 
whose tumors were in vitro sensitive. This cooperative clinical 
trial confirmed the feasibility to predict resistance of cancer 
in vitro before starting chemotherapy and the relevance for clini-
cal treatment. In a further study (Figures 2D,E), we investigated 
surgical adenocarcinoma specimens of the lung (stage III) and 
compared the in  vitro short-term test results with survival of 
patients treated with chemotherapy (16). Thirty-two patients 
with previously untreated adenocarcinoma of the lung (stage III, 
pT, pN) were included in this investigation. The minimum fol-
low up time was 5 years. Fourteen patients were only treated by 
surgical procedures (group S), and 18 patients were additionally 
treated with cytotoxic drugs (CT group). The chemotherapy pro-
tocols used were (a) doxorubicin/cyclophosphamide/vincristine 
and (b) BCNU/5-fluorouracil, and (c) cisplatinum/vindesine. 
The survival curves did not differ between the S and CT groups 
(log-rank p = 0.63; rank-sum p = 0.39) (Figure 2D). However, 
if we reanalyzed the same data on the basis of the in vitro short-
term test results, a different pattern emerged. The CT patients, 
(A) The effects of different doxorubicin concentrations on doxorubicin-resistant or doxorubicin-sensitive ascites tumor cells of murine sarcoma 180 in vivo (left). 
Resistant tumor cells grown in mice were treated with doxorubicin (3 × 0.5 mg/kg BW per week) during 25 passages. The cytotoxic effect was measured by 
determination of the cell count. Average values ± SD are from seven tumors at each point. Corresponding results (middle) using the in vitro short-term test. After 
incubation of the tumor cells with different concentration of doxorubicin for 2 h, radioactive nucleic precursors (3H-uridine) were added for another hour. The 
non-incorporated radioactivity was extracted and the incorporated radioactivity determined by liquid scintillation counting. Uptake values were expressed as 
percentages of controls. Right: survival curves of mice bearing sensitive or resistant sarcoma S180 cells without or with doxorubicin treatment. Without therapy, the 
survival times for the animal with sensitive or resistant tumors were the same. With therapy, the survival times of both groups were significantly different. n = 60 
mice. Data were taken from Ref. (9). (B) The effect of different concentrations of doxorubicin in slowly growing (1 = neurosarcoma) and rapidly growing (2 = Walker 
carcinosarcoma) animal tumors. Left: tumor size under therapy (square millimeter). Average values ± SD were from seven tumors at each point (n = 84 rats). Middle: 
3H-uridine incorporation in vitro. Values (% of controls) were the averages from two tumors with duplicate determinations. Data were taken from Ref. (7). Right: 
relationship between tumor growth and cytostatic activity in various transplantation tumors (adenocarcinoma, sarcoma S180, melanoma FIII, and multiple myeloma) 
grown in different species (mouse, rat, and hamster). Right, top: tumor increase in vivo within 1 day (square millimeter). Right, bottom: 3H-Thymidine incorporation 
in vitro (cpm). Data were taken from Ref. (7). (C) The proliferation-dependent drug resistance in animal and human tumors. The variable tumor response to 
doxorubicin in vitro was assayed with a fixed concentration of 10−2 mg/ml (left and middle). Right: survival curves of patients with ovarian carcinomas subdivided 
according to the cell cycles phases (proportion of SG2M-phases ≤ or >17%). Flow cytometric analyses were carried out using an ICP-22 (PHYWE AG, Göttingen, 
Germany). For measurements of DNA content, a mixture of propidiumiodide and 4–6-diamidino-2-phenylindole was simultaneously applied with RNAse after 
methanol fixation and protease digestion. Data were taken from Ref. (11).
FiGURe 1 | Continued
FiGURe 2 | (A) Comparison of results of the in vitro short-term test and clinical chemotherapy of human tumors. Values represent the inhibition (%) of 3H-uridine 
incorporation. Closed symbols, tumors responsive to clinical chemotherapy. Open symbols, Tumors non-responsive to clinical chemotherapy. Data were taken from 
Ref. (15). Overall survival curves of patients with (B) ovarian carcinoma or (C) lung carcinoma separated into either resistant or sensitive groups according to the 
in vitro short-term test results. Data were taken from Ref. (15). (D) Of the 32 patients with previously untreated adenocarcinoma of the lung (stage III), 14 were 
treated with surgery alone (group S) and 18 were treated with surgery plus chemotherapy (group CT). The survival curves were not different between the S and CT 
groups (log-rank p = 0.63, rank-sum p = 0.39). (e) However, when the same data were analyzed on the basis of the in vitro short-term test, a different pattern 
appeared. CT patients with in vitro sensitive tumors were lived significantly longer than those with resistant tumors (log-rank p = 0.023, rank-sum p = 0.006). Data 
were taken from Ref. (16).
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TABLe 1 | Predictive value of drug resistance assays.
Assay Tumor type No. of 
patients
Predictive accuracy Reference
Original investigations
Tumor clonogenic assay Ovarian Ca 44 99% resistance prediction; 62% sensitivity prediction Alberts et al. (17)
3H-thymidine and 3H-uridine 
incorporation
Ovarian Ca 84% resistance prediction; 79% sensitivity prediction Khoo et al. (18)
Extreme drug resistance assay Ovarian Ca 46 100% resistance prediction; 58% sensitivity prediction Kern et al. (19)
Fluroescent cytofootprint assay Ovarian Ca 72 96% resistance prediction; 71% sensitivity prediction Blackman (20)
Tumor clonogenic assay Ovarian Ca 93 83% resistance prediction; 50% sensitivity prediction Federico et al. (21)
ATP luminescence assay Ovarian Ca 100 >90% resistance prediction (70 untreated, 30 refractory) Andreotti et al. (22)
Fluroescent cytofootprint assay Ovarian Ca 47 100% resistance prediction; 56% sensitivity prediction Csoka et al. (23) 
MTT assay Ovarian Ca 37 85% resistance prediction; 65% sensitivity prediction Taylor et al. (24) 
ATP luminescence assay Ovarian Ca 38 89% resistance prediction; 66% sensitivity prediction Konecny et al. (25) 
MTT assay Ovarian Ca 120 83% resistance prediction Taylor et al. (26)
3H-thymidine incorporation Ovarian Ca 25 100% resistance prediction; 60% sensitivity prediction Hetland et al. (27)
ATP luminescence assay Ovarian Ca 61 79% resistance prediction; 60% sensitivity prediction Neubauer et al. (28)
Sulforhodamine B assay Peritonitis carcinomatosa 
of ovarian Ca
28 89.5% resistance prediction; 62.5% sensitivity prediction Arienti et al. (29)
3H-thymidine incorporation Breast Ca 41 81% resistance prediction; 75% sensitivity prediction Daidone et al. (30)
Extreme drug resistance Breast Ca 48 100% resistance prediction; 47% sensitivity prediction Kern (19)
Fluroescent cytofootprint assay Breast Ca 47 100% resistance predition; 91% sensitivity prediction Blackman (20)
ATP luminescence assay Breast Ca 17 86% resistance prediction; 90% sensitivity prediction Kochli et al. (31)
3H-uridine incorporation Breast Ca 25 94% resistance prediction; 71% sensitivity prediction Elledge et al. (32)
MTT assay Breast Ca 83 80% resistance prediction; 61% sensitivity prediction Xu et al. (33)
MTT assay Breast Ca 73 100% resistance prediction; 76.7% sensitivity prediction Xu et al. (34)
3H-thymidine incorporation, tumor 
clonogenic assay
Gynecological Ca 63 <50% sensitivity prediction; 90% resistance prediction Eidtmann et al. (35)
3H-thymidine incorporation Gynecological Ca 108 72% resistance prediction; 85% sensitivity prediction Khoo et al. (36)
MTS assay Gynecological Ca 45 93.3% resistance prediction; 86.7% sensitivity prediction O’Toole et al. (37)
ATP luminescence assay Gastric Ca 36 95.7% resistance prediction; 46.2% sensitivity prediction Kim et al. (38)
ATP luminescence assay Gastrointestinal Ca 25 100% resistance prediction; 64% sensitivity prediction Kawamura et al. (39)
ATP luminescence assay Esophageal Ca 68.8% resistance prediction; 77.8% sensitivity prediction Hirai et al. (40)
Tumor clonogenic assay Liver Ca and liver 
metastasis
36 71% resistance prediction; 55% sensitivity prediction Link et al. (41)
Tumor clonogenic assay Liver Ca 24 91% resistance prediction; 77% sensitivity prediction Link et al. (42)
Tumor clonogenic assay Melanoma 50 Retrospective: 100% resistance prediction; 38% sensitivity 
prediction
Tveit et al. (43)
Tumor clonogenic assay Melanoma 55 Prospective: 100% resistance prediction; 60% sensitivity 
prediction
Tveit et al. (43)
ATP luminescence assay Melanoma 53 83.9% resistance prediction; 36.4% sensitivity prediction Ugurel et al. (44)
Tumor clonogenic assay Lung cancer 326 91% resistance prediction; 60% sensitivity prediction Kitten et al. (45)
Tumor clonogenic assay Lung cancer 20 86% resistance prediction; 83% sensitivity prediction Bertelsen et al. (46)
Dye exclusion assay Lung Ca (SCLC) 21 82% resistance prediction; 55% sensitivity prediction Gazdar et al. (47)
Collagen gel droplet embedded 
culture drug sensitvity test (CD-DST)
Lung Cancer (NSCLC) 49 100% resistance prediction; 72.7% sensitivity prediction Kawamura et al. (48)
Tumor clonogenic assay Glioma 470 100% resistance prediction; 60% sensitivity prediction Alonso (1984) (49)
Flow cytometry of DNA integrity Glioma 41 81% resistance prediction; 86% sensitivity prediction Iwadate et al. (50)
Dye exlusion assay Acute leukemia 31 33,3% resistance prediction; 86.7% sensitivity prediction Hwang et al. (51)
MTT assay Acute leukemia 31 77,8% resistance prediction; 91.3% sensitivity prediction Hwang et al. (51)
Tumor clonogenic assay, 
3H-thymidine incorporation
Multiple myeloma 97 73% sensitivity prediction; 83% resistance prediction Durie et al. (52)
3H-tymidine in corporation Diverse 33 100% resistance prediction; 46.2% sensitivity prediction Sondak et al. (53)
3H-thymidine incorporation Diverse 20 93% resistance prediction; 67% sensitivity prediction Wada et al. (54)
CD-DST Diverse 554 100% resistance prediction; 80% sensitivity prediction Kobayashi et al. (55)
Tumor clonogenic assay of  
xenograft tumors
Diverse 80 62% sensitivity prediction; 97% resistance prediction Fiebig et al. (56)
ChemoFx® test Squamous cell Ca,  
adeno Ca
285 58% resistance prediction; 87% sensitivity prediction Grigsby et al. (57)
(Continued)
December 2015 | Volume 5 | Article 2826
Volm and Efferth Prediction of Cancer Drug Resistance
Frontiers in Oncology | www.frontiersin.org
Assay Tumor type No. of 
patients
Predictive accuracy Reference
Reviews
Tumor clonogenic assay Diverse (review) 96% resistance prediction; 62% sensitivity prediction Salmon et al. (58)
Tumor clonogenic assay Diverse (review) >1500 92% resistance prediction; 57% sensitivity prediction Bertelsen et al. (59)
Tumor clonogenic assay Diverse (review) 91% resistance prediction; 71% sensitivity prediction Salmon et al. (60)
Diverse Glioma (review) 100% resistance prediction; 50-70% sensitivity prediction Kimmel et al. (61)
Subrenal capsule assay Diverse (review) 1400 73% resistance prediction; 91% sensitivity prediction Bodgen and Cobb (62)
Diverse Review of 54 retrospective 
studies
2300 91% resistance prediction; 69% sensitivity prediction von Hoff et al. (63)
Fluorescent cytoprint assay Diverse (review) 91% resistance prediction; 86% sensitivity prediction Meitner et al. (64)
Diverse Diverse (review) 1100 93% resistance prediction; 46.7% sensitivity prediction Kondo et al. (65)
CD-DST Diverse 183 88.8% resistance prediction; 79.8% sensitivity prediction Kobayashi et al. (66)
Tumor clonogenic assay Diverse (review) 2300 91% resistance prediction; 69% sensitivity prediction Fiebig et al. (56)
Tumor clonogenic assay Diverse (review) 66 92% resistance prediction; 62% sensitivity prediction Fiebig et al. (56)
Diverse assays Ovarian Ca (review) 1101 93% resistance prediction; 46.6% sensitivity prediction Kubota and Weisenthal 
(67)
Diverse assays Diverse tumor types 
(review)
4092 90.3% resistance prediction; 71,7% sensitivity prediction Blumenthal et al. (6)
Diverse Review of 86 studies 1945 87.4% resistance prediction; 80.0% sensitivity prediction Weisenthal (68)
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whose tumors were in  vitro sensitive lived significantly longer 
than those with in  vitro resistant tumors (log-rank p =  0.023, 
rank-sum p =  0.006) (Figure  2E). The median survival times 
were 185  weeks for patients with in  vitro sensitive tumors 
and 31  weeks for the patients with in  vitro resistant tumors. 
Importantly, there was a statistically significant positive cor-
relation (r = 0.7) between the degrees of doxorubicin-induced 
inhibition of 3H-uridine uptake and patients’ survival times. As 
expected, the survival times of patients treated with surgery, but 
not chemotherapy, did not correlate with the in vitro test results 
(16). Thus, the observed differences in survival times of patients 
treated with surgery plus chemotherapy were specific and can be 
attributed to drug therapy.
Again, we have compared our own data with published results 
of more than 1900 patients in the literature. As shown in Table 2, 
patients with tumors that appeared as being sensitive in drug 
resistance testing had a better survival outcome than patients 
with drug-resistant tumors. This has been observed in the vast 
majority of patients independent of which tumors they were 
suffering from or which cytostatic drug has been used for testing.
BROAD SPeCTRUM ReSiSTANCe
If a tumor responded to doxorubicin by means of the in  vitro 
short-term test, in the majority of cases similar effects can be 
detected with other cytostatic agents, i.e., tumors insensitive 
to doxorubicin are also insensitive to other drugs (Figure 3A). 
Statistically significant correlations existed between the inhibitory 
effect of doxorubicin, daunorubicin, 5-fluorouracil, actinomycin 
D, and cyclophosphamide (8). The correlation coefficient for the 
in vitro activities of doxorubicin and daunorubicin was r = 0.864 
and that for doxorubicin and 5-fluorouracil r =  0.779. Similar 
correlations were also observed between the activities of doxoru-
bicin and actinomycin D (r = 0.907) as well as of doxorubicin and 
cyclophosphamide (r = 0.710).
In the 1980s and 1990s, a resistance phenomenon has been 
investigated termed multidrug resistance (MDR), which is caused 
by the drug efflux transporter P-glycoprotein. MDR comprises 
cross-resistance of tumor cells to anthracyclines, Vinca alkaloids, 
taxanes, and epipodophyllotoxins, but not to alkylating agents 
and antimetabolites (88, 89).
Therefore, we were interested, whether or not the cross-
resistance profile observed in our approach was compliant with 
the MDR phenotype (87). We analyzed 59 tumors of different 
origin for their in  vitro resistance to anthracyclines (doxoru-
bicin, daunorubicin), antibiotics (dactinomycin, bleomycin), 
antimetabolites (5-fluorouracil, methotrexate), epipodophyl-
lotoxins (mitopodozide), and alkylating agents (procarbazine, 
triaziquone) by means of the in vitro short-term test.
As a next step, we performed hierarchical cluster analysis, 
which may be more suited for an integrated approach to under-
stand the complexity of drug resistance. All investigated drugs 
except doxorubicin were subjected to cluster analysis (Figure 3B, 
left). We divided the dendrogram into six clusters and correlated 
them with the doxorubicin results. Interestingly, sensitive and 
resistant tumors were separated in the clusters (p = 2.5 × 10−7). 
Clusters 1, 5, and 6 (n =  31) were enriched with doxorubicin-
resistant tumors (54%), whereas clusters 2, 3, and 4 (n =  28) 
were enriched with doxorubicin-sensitive ones. This indicates 
that resistance to nine compounds from different drug classes 
(antibiotics, antimetabolites, epipodophyllotoxins, and alkylating 
agents) significantly correlated with resistance to doxorubicin. 
This opens the possibility to predict the responsiveness of tumors 
to a broad range of cytostatic drugs by using solely doxorubicin as 
a reference drug. To further explore this phenomenon in a group 
of tumors of the same tumor type, we investigated 38 lung cancers 
for their response in  vitro to doxorubicin, 5-fluorouracil, and 
4-OOH-cyclophosphamide (Figure 3B, middle). Cluster analysis 
using the data for 5-fluorouracil and 4-OOH-cyclophosphamide 
allowed the separation of three clusters. Again, we found a 
TABLe 1 | Continued
TABLe 2 | Prognostic value of drug resistance assays.
Assay Tumor type No. of 
patients
Prognostic relevance Reference
MTT assay Ovarian Ca 120 Survival benefit of sensitive vs. resistant Taylor et al. (26) 
Extreme drug resistance assay Ovarian Ca 79 Survival benefit of sensitive vs. resistant Holloway et al. (69)
3D-histoculture assay Ovarian Ca 164 Survival benefit of sensitive vs. resistant Nakada et al. (70)
ChemoFx® test Ovarian Ca 147 Survival benefit of sensitive vs. resistant Herzog et al. (71)
3D-histoculture assay Ovarian Ca 104 Survival benefit of sensitive vs. resistant Jung et al. (72)
MTT assay Ovarian Ca 120 Survival benefit of sensitive vs. resistant Xu et al. (73)
3D-histoculture assay Peritonitis 
carcinomatosa
18 Survival benefit of sensitive vs. resistant Isogai et al. (74)
Three-dimensional histoculture Gastric Ca 128 Survival benefit of sensitive vs. resistant Kubota et al. (75)
Three-dimensional histoculture Gastric Ca 32 Survival benefit of sensitive vs. resistant Furukawa et al. (76)
MTT assay Gastric Ca 28 Survival benefit of sensitive vs. resistant Abe et al. (77)
3D-histoculture assay Gastric Ca 100 No survival benefit of sensitive vs. resistant Kodera et al. (78)
MTT assay Gastric Ca 353 No survival benefit of sensitive vs. resistant Wu et al. (79)
MTT assay Gastric Ca 50 Survival benefit of sensitive vs. resistant Kubota et al. (80)
Three-dimensional histoculture Colorectal cancer 29 Survival benefit of sensitive vs. resistant Furukawa et al. (76)
MTT assay Colorectal Ca 200 Survival benefit of sensitive vs. resistant Kabeshima et al. (81)
MTT assay Pancreas Ca 14 Survival benefit of sensitive vs. resistant Yamaue et al. (82)
ATP luminescence assay Pancreas Ca 18 Sensitive tumors have lower risk of treatment failure than 
resistant ones
Michalski et al. (83) 
MTT assay Esophageal Ca 46 Survival benefit of sensitive vs. resistant Nakamori et al. (84)
ATP luminescence assay Melanoma 53 Survival benefit of sensitive vs. resistant Ugurel et al. (44)
ATP luminescence assay Melanoma 14 Survival benefit of sensitive vs. resistant Doerler et al. (85)
Collagen gel droplet embedded culture drug 
sensitvity test (CD-DST)
Lung cancer 
(NSCLC)
49 Survival benefit of sensitive vs. resistant Kawamura et al. (48)
ATP luminescence assay Leukemia (ANLL) 23 Survival benefit of sensitive vs. resistant Möllgård et al. (86)
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statistically significant relationship between resistance to doxo-
rubicin and resistance to the other drugs (p = 1.10 × 10−3) in 21 
leukemia examples. To validate this result on lung cancer as a 
solid tumor type, we subsequently used leukemia as single cell 
cancer. Similar to doxorubicin, daunorubicin as anthracycline of 
choice for leukemia treatment predicted resistance to other drugs 
(etoposide, cytosine, arabinoside, 6-thio-guanine) as determined 
by cluster analysis (p = 1.29 × 10−4) (Figure 3B, right). In addition 
to a possible value of doxorubicin as reference compound for the 
in vitro short-term test, another conclusion of these investigations 
is that tumors exert cross-resistance profiles that are broader 
than the classical P-glycoprotein-mediated MDR phenotype. 
Therefore, we have used the term “broad spectrum resistance.” 
Our point of view on clinical drug resistance phenomena has 
been recently supported by comparable observations described 
as “pan-resistance” (90).
Our cluster analyses revealed that clusters of sensitive or resist-
ant tumors could be predicted by one single drug, doxorubicin. 
This speaks for the high predictive power of doxorubicin to detect 
broad spectrum resistance. The pleiotropic modes of action of 
doxorubicin might explain, why doxorubicin is capable of pre-
dicting broad spectrum resistance.
1. Doxorubicin is transported by P-glycoprotein and, therefore, 
is involved in the MDR phenotype. Therefore, doxorubicin 
can predict response to antibiotics, Vinca alkaloids, and 
epipodophyllotoxins.
2. Doxorubicin inhibits DNA topoisomerase II, which is neces-
sary for cell division. The activity of doxorubicin is depend-
ent on the proliferative activity of tumor cells. Therefore, 
doxorubicin may predict the responsiveness of tumors to 
other drugs, which also act in a proliferation-dependent 
manner, such as antimetabolites, i.e., 5-fluorouracil.
3. The inhibition of DNA topoisomerase II by doxorubicin 
induces DNA strand breaks. Because alkylating agents also 
damage DNA, doxorubicin may predict the response to 
alkylators, such as 4-OOH-cyclophosphamide.
4. Doxorubicin as well as alkylating agents generates reactive 
oxygen species and radical carbon-centered molecules. This 
represents another explanation for the predictive power of 
doxorubicin toward alkylating drugs.
This enables to conduct predictive tumor tests with drugs not 
included in the therapy schedule. According to our investigations 
on human tumors, tests using doxorubicin appear to be sufficient 
to detect drug resistance. Therefore, the in vitro short-term test 
should be generally not used to find the most effective compound 
in individual tumors, but merely to determine whether a tumor 
responds at all to any chemotherapy.
THe MULTiFACTORiAL NATURe OF 
CANCeR DRUG ReSiSTANCe
Having in mind that tumors tend to be sensitive or resistant not 
only to single but also to multiple drugs at the same time, it can 
be speculated that multiple factors rather than single mechanisms 
may account for broad spectrum or pan-resistance (87, 90). For 
this reason, we investigated a battery of diverse factors for their 
expression levels in lung tumors and compared these expressions 
with the results of the in  vitro short-term test. The rationale 
FiGURe 3 | (A) Cross-resistance of doxorubicin to daunorubicin, 5-fluorouracil, actinomycin D, and cyclophosphamide in various human tumor types as measured 
by the in vitro short-term test. (B) Hierarchical cluster analyses of response of clinical tumor specimens toward different antitumor drugs from different drug classes: 
doxorubicin, daunorubicin (anthracyclines), actinomycion D, bleomycin (antibiotics), 5-fluorouracil, methotrexate (antimetabolites), mitopodozide 
(epipodophyllotoxins), and procarbazine, triaziquone (alkylating agents). Dendograms obtained from clustering of 59 diverse tumors, 38 lung carcinomas, and 21 
leukemia [data are taken from Ref. (87)].
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for these analyses was substantiated by the fact that increasing 
evidence emerged in the literature for a variety of many different 
drug resistance mechanisms, which are all operative in clinically 
resistant tumors (5, 13, 88, 91–100). The question arises, as to 
which resistance factors may be recognized by the in  vitro 
short-term test. Therefore, we determined a total of more than 
50 resistance-related factors in 94 human non-small cell lung car-
cinomas by immunohistochemistry (101). These factors can be 
categorized as resistance proteins, proliferation-related proteins, 
oncoproteins and tumor suppressor proteins, proteins regulating 
apoptosis, and angiogenic factors.
The expression of 28 out of >50 proteins significantly cor-
related with doxorubicin resistance in the in  vitro short-term 
test. Of them, the expression of nine proteins directly correlated 
and another 19 proteins inversely correlated with resistance to 
doxorubicin.
Some representative examples are shown in Figures  4A,B. 
Three examples of resistance proteins that were directly associ-
ated with doxorubicin resistance were P-gp, GST-pi, and MT 
(Figure 4A). These histograms demonstrate that the number of 
tumors with high protein expression levels (as determined by 
semi-quantitative immunoscores) increased with doxorubicin 
resistance.
Figure 4B shows three examples of factors that inversely cor-
related with resistance, i.e., PCNA, FAS/CD95, and VEGF. Here, 
rather low than high protein expression was related to doxorubicin 
resistance. Hence, the number of tumors with high expression of 
these proteins was higher in sensitive tumors. As a next step, we 
calculated the mean protein expression values of all sensitive or 
resistant tumors and plotted them in an oncobiogram. Figure 4C 
shows a synopsis of all resistance factors that significantly cor-
related with doxorubicin resistance. It can be clearly seen that the 
mean expressions of all of these factors were lower in sensitive 
tumors compared to resistant ones.
These analyses clearly indicate that we have to take multiple 
rather than single factors into account as mode of action of drug 
resistance. To prove this assumption, we determined the number 
of resistant tumors co-expressing more than one resistance factor. 
Figure 4D shows that the number of resistant tumors express-
ing four resistance factors was highest, whereas the number of 
resistant tumors with three, two, one, or no factor was gradually 
decreasing. This clearly speaks for the multifactorial nature of 
drug resistance and that single resistance factors are not sufficient 
to explain resistance phenomena in clinical lung tumors.
In addition, we tested whether combinations of resistance 
factors may improve the prediction of the degree of resistance. 
Indeed, the degree of resistance increased with the number of 
resistance markers (Figure 4E).
CONCLUSiON
Data obtained from multiple sources, including in  vitro drug 
resistance testing, immunohistochemical determination of 
resistance-related proteins, and clinical data, indicate that no 
single drug resistance mechanism can explain drug resistance. 
Resistance mechanisms are numerous and diverse. They depend 
on the detoxifying capacity of cells, tissue-specific factors, repair 
capacity, drug delivery, cell proliferation, angiogenesis, apoptosis, 
and many other factors. Additionally mutation or amplification of 
specific genes involved in protective pathways as well as the muta-
tion of different oncogene or suppressor genes may be responsible 
for resistance to chemotherapy. It becomes evident that cancer 
cells utilize multiple pathways to overcome the cytotoxic effect 
of drugs used during chemotherapy. Resistance tests should, 
therefore, recognize these pathways. Our studies attempted to 
discover the important cellular predictive factors. A key future 
challenge involves determining the relative contributions of each 
of these mechanisms.
During the past four decades, various in vitro test procedures 
have been developed used to test sensitivity or resistance. Kubota 
and Weisenthal reported on in vitro and in vivo results in 1101 
gastrointestinal tumors (67). The correlation of in  vitro and 
in vivo results revealed 215 true-sensitive (S/S), 246 false-sensitive 
(S/R), 595 true-resistant (R/R), and 45 false-resistant (R/S), 
resulting in a 47% true-sensitive rate and a 93% true-resistant 
rate. Blumenthal and Goldenberg summarized the correlation of 
the in vitro results of different assay types with patients’ response 
(6). Of 4092 in vitro assays, 1809 were sensitive and 2283 resist-
ant. The correlation of in vitro and in vivo results showed 1297 
true-positive patients, who were sensitive in vitro and respond to 
therapy (S/S), 512 false-positive, who were sensitive in vitro, but 
resistant clinically (S/R), 2061 true-negative patients, who were 
resistant in vitro and did not respond to therapy (R/S), and 222 
false-negative patients, who were resistant in vitro but responded 
clinically (R/S). The sensitivity was estimated as true in 72% and 
the resistance in 90% of the cases. Our data are in agreement with 
all these investigations.
Nevertheless, none of these predictive in vitro tests have been 
clinically established for routine diagnostics. The American 
Society for Clinical Oncology (ASCO) does not recommend 
in  vitro tests for the prediction of chemosensitivity (102, 103). 
This raises the question as to why clinical translation did not take 
place, despite numerous investigations speaking for the feasibility 
of such test systems. An explanation might be the predictive accu-
racy to detect sensitive and resistant tumors. A close inspection 
of the data from us and others indicate that independent of the 
specific test method, drug resistance can be detected with high 
accuracy (>90%), whereas drug sensitivity can be detected with 
true-positive rates of only about 40–70%. Hence, the correct con-
clusion from these data is that all these methods are not reliable 
enough as clinically useful chemosensitivity tests. However, at the 
same time it can be stated that drug resistance can be predicted 
with high reliability. The reasons for this striking difference in 
predictive power to distinguish between sensitive and resistant 
tumors may be numerous.
Chemosensitivity of tumor cells detected ex vivo under 
artificial laboratory conditions does not necessarily comply with 
the specific situation of a patient. For instance, effective levels of 
antineoplastic agents in tumors may not be reached, if tumors 
are poorly vascularized. Hepatic biotransformation of drugs or 
interaction between drugs may also play a role in vivo. For these 
reasons, false-positive results (sensitive in  vitro, but resistant 
in vivo) can be expected to occur more frequently than vice versa. 
A major concept of all the different predictive in vitro tests was 
FiGURe 4 | Relationship between the expression of resistance factors in 94 non-small cell lung carcinomas immunohistochemistry and resistance to 
doxorubicin as determined by the in vitro short-term test. The factors show no reaction (−) weak (+), moderate (+ +) or strong reaction (+ + +). (A) 
Representative examples of factors directly correlating with resistance. (B) Representative examples of factors inversely correlating with resistance. (C) Oncobiogram 
of resistance factors in sensitive tumors (dotted line) and resistant tumors (bold line). (D) Number of resistant tumors expressing no or one resistance factor or 
co-expressing two to four factors (P-gp, GST-pi, TS, MT). (e) Number of resistance markers in relationship to the degree of resistance. Abscissa: 0, no resistance 
marker; 1, one resistance marker, 2, two resistance markers, 3, three resistance markers (P-gp, GST-pi, or TOP2). Ordinate: inhibition by doxorubicin (10 μg/ml) as 
measured by the in vitro short-term test. Abbreviations: P-gp, P-glycoprotein; GST-pi, glutathione S-transferase-pi; MT, metallothionein; PCNA, proliferation cellular 
nuclear antigen; FAS/CD95, Fas ligand; VEGF, vascular endothelial growth factor; TS, thymidylate synthase; FOS, Fos oncoprotein; LRP, lung resistance protein; 
RB1, retinoblastoma protein 1; PAI, plasminogen activator inhibitor; PAR, plasminogen activator receptor; BAX, Bcl2 family member; O6-MGMT, O6-methylguanine 
DNA-methyltransferase. (Data are taken from Ref. (101)).
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to identify drugs a priori which tumors are most sensitive to, in 
order to use them for subsequent therapy. Hence, scientists and 
oncologists alike were hunting for the optimal chemosensitivity 
test. The facts after all these years of research teach us that it may 
not be possible to find such an optimal test system. Therefore, 
it is time now to rethink and question this concept. Instead of 
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testing chemosensivity, these in vitro tests may be used to identify 
those tumors that are drug resistant with the aim not to treat them 
with chemotherapy at all. In the past decades, this option may 
have appeared less attractive, as oncologists cannot leave patients 
alone with the message “Sorry, your tumor is resistant, we cannot 
do anything for you.” This is frustrating for both, patients and 
physicians. Nowadays, the situation is changing, as novel treat-
ment options are emerging. Patients diagnosed as being drug 
resistant with the help of such predictive tests may be treated 
with other therapy strategies, such as antibody therapy, adoptive 
immune therapy, hyperthermia, and in the future may be also 
with aptamer therapy, gene therapy, and others.
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